I'm new to this stock; I just bought some today after doing some research on this stock. I found a postive phase 2 clinical trial dated October 4, 2012 that found that a single oral dose of Solithromycin cleared infections in patients with uncomplicted urogenital gonorrhea. With gonorrhea being the second most commonly reported infection in the United States and the CDC's announcement that cefixime (Suprax), the single oral drug previously recommended, can no longer be considered a reliabel therapy there could be a huge market here for Solithromycin. To see the full report go to Bing and do a search on: cemp gonorrhea (do not use quotation marks) and one of the top results should be titled: "Cempra, Inc. Announces Positive Top Line Results"; click on that result.